Advertisement

Topics

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

09:54 EDT 23 Sep 2016 | SCRIP

Efforts by CDER management to encourage more interaction between patients and FDA reviewers may be part of the collateral damage...

      

Related Stories

 

Original Article: Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

NEXT ARTICLE

More From BioPortfolio on "Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta"

Quick Search
Advertisement